Year Founded
2000
Ownership
Private
Employees
~100
Stage
Commercial
Modalities
Small molecule

Plexxikon General Information

Successfully developed Zelboraf (vemurafenib) for melanoma which was approved. Company was acquired by Daiichi Sankyo in 2011.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Berkeley, California
United States

Drug Pipeline

vemurafenib
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Plexxikon's pipeline data

Book a demo

Key Partnerships

Roche, Daiichi Sankyo

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Plexxikon Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Plexxikon's complete valuation and funding history, request access »

Plexxikon Investors

Advanced Technology Ventures
Investor Type: Venture Capital
Holding: Minority
Alta Partners
Investor Type: Venture Capital
Holding: Minority
Walden International
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »